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BMP is highly expressed in glioblastoma and promotes differentiation of cancer stem cells (CSCs). Recently,
Yan and colleagues found the explanation to this apparent paradox by showing that the antagonist of BMP,
Gremlin1, is secreted by CSCs to protect them against the BMP-induced differentiation.Tumors often consist of a diverse mosaic
of cells exhibiting different genomic
alterations and epigenomic status and
receiving multiple and pleiotropic extra-
cellular signals. This implies that tumors
contain functionally heterogeneous can-
cer cells with different sensitivities to
pharmacological compounds. Within the
concept of intratumoral heterogeneity,
there is now evidence (through transplan-
tation and lineage tracing experiments)
of a population of cells that are more
tumorigenic than the rest, are more resis-
tant to DNA damage, and possess a
higher capacity to reinitiate tumors. This
cell population, called cancer stem
cells (CSCs) or cancer-initiating cells,
is thought to be in part responsible for
tumor relapse and metastasis, making
CSCs a crucial therapeutic target. CSCs
are considered to have stem cell charac-
teristics including the ability to self-renew
or differentiate (Visvader and Lindeman,
2012).
The balance between CSC self-renewal
and differentiation is crucial for tumor
development, and it is regulated by
external cues including transforming
growth factor b (TGF-b), Notch, Hedge-
hog, and Wnt. Work over the past
years has shed light onto the role of the
TGF-b superfamily of cytokines, including
BMPs and TGF-bs, in the control of CSC
biology. Interestingly, BMP and TGF-b,
being members of the same family,
exhibit opposed functions in the context
of CSCs. Although BMP has been shown
to induce CSC differentiation (Lee et al.,
2008; Piccirillo et al., 2006), TGF-b has
been described to induce CSC self-
renewal (Ikushima et al., 2009; Pen˜uelas
et al., 2009).716 Cancer Cell 25, June 16, 2014 ª2014 ElsYan et al. (2014) discerned the
mechanism through which CSCs in glio-
blastoma (GBM) escape BMP-induced
differentiation. Because BMP induces
CSC differentiation, promoting the loss
of CSCs within the tumor, one could pre-
dict that BMP is a tumor suppressor.
However, BMP is highly expressed
in several tumor types, including GBM.
To understand this paradox, the au-
thors studied the molecular mechanisms
through which BMPs regulate CSC
self-renewal. CSCs were isolated from
patient samples based on the expression
of CD133, and gene expression of CSCs
versus non-CSCs was compared. They
soon realized that CSCs isolated from
GBM tumors exhibit decreased activity
of the BMP pathway and, most impor-
tantly, they highly express Gremlin1. Be-
ing a morphogen with a critical function
in embryonic development, BMP activity
levels are exquisitely regulated at many
different levels. One way to control the
BMP cellular response is through the
regulation of ligand access to the recep-
tor. Several secreted BMP antagonists,
including Gremlin1, act as decoys and
sequester BMP ligand to prevent activa-
tion of the BMP pathway (Wakefield and
Hill, 2013).
Yan et al. (2014) showed that, despite
the high expression of BMP in GBM,
CSCs escape the BMP differentiating
effect by secreting Gremlin1 (Figure 1).
Moreover, they went on to identify the
main mediator of Gremlin1 effects on
CSC differentiation. Gene expression
analysis and further bioinformatic studies
identified the CDK inhibitor p21 as the
master regulator of a set of genes differ-
entially expressed after knocking downevier Inc.Gremlin1. Interestingly, inhibition of p21
by Gremlin1 was independent of p53,
and p21 was regulated at the posttran-
scriptional level. p21 is a critical regulator
of cell proliferation inducing cell cycle
arrest in the G1 phase, can regulate
apoptosis, and can act as a transcription
factor. Importantly, p21 has been re-
ported to be involved in the control of
stem cell self-renewal (Warfel and El-
Deiry, 2013). However, the effect of p21
on stem cell self-renewal is diverse and
depends on the cellular context. On the
one side, p21 has been shown to facilitate
stem cell self-renewal, while, in other situ-
ations, p21 stops cell cycle arrest and
promotes differentiation. Yan et al.
(2014) consider that, in their system, p21
acts as an inducer of differentiation.
Moreover, p21 is a well-known target of
BMP, suggesting that the function of
Gremlin1 could consist of preventing
the induction of p21 by BMP and
consequently inhibiting p21-induced
differentiation.
Yan and colleagues found the clue to
solve the BMP pathway paradox in GBM
when considering the mechanism of ac-
tion of BMP in the context of embryonic
development. Cancers often co-opt mo-
lecular mechanisms involved in normal
embryonic development to their benefit.
The exquisite regulation of the BMP
pathway found to be crucial for the cor-
rect cellular patterning during develop-
ment is used in cancer to shield CSCs
against differentiation. Gremlin1, a critical
factor for cell specification, through the
control of the exact physiological activity
of the morphogen BMP, is secreted by
CSCs in GBM to promote CSC self-
renewal and maintain a pool of CSCs in
Figure 1. Cancer Stem Cells Secrete the BMP-Antagonist Gremlin1
to Prevent the BMP-Induced Differentiation of Cancer Stem Cells
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Previewsthe tumor despite the pres-
ence of high BMP levels.
As expected, this study
opens an avenue of ques-
tions that warrant further
research. For instance, how
general is the phenomenon?
Does this happen in all GBM
tumors or in only some GBM
subtypes (i.e., proneural and
mesenchymal GBM)? The
authors show that mutations
in p53 do not impair the effect
of Gremlin1 on CSCs, but are
there other genomic alter-
ations (i.e., mutations in NF1
or PDGFR) that affect this
phenomenon? It has been
described that the differenti-
ating capacity of BMP de-
pends on the methylation
status of the BMPR1b gene
(Lee et al., 2008). Is that
required for the effect of
Gremlin1 on CSCs? The au-
thors based their studies on
CSCs that express the mem-
brane marker CD133, but,
because there are other CSCmarkers (i.e., CD44, CD15, the side
population assay), is the described mech-
anism taking place in CSCs expressing
other markers besides CD133? Or, is it
possible that different GBM tumors pre-
sent different CSC entities that could
be regulated by alternative pathways?
Importantly, all these questions have a
crucial interest in the clinical context
when considering Gremlin1 as a thera-
peutic target. It will be necessary to iden-
tify the tumors in which Gremlin1 acts
as an oncogenic factor to select the
patients who might benefit from Gremlin1
blockade.
This work still leaves another paradox
unexplained. BMP is an inducer of the
transcription factor Id1 (Lo´pez-Rovira
et al., 2002), which is highly expressed in
CSCs. Moreover, TGF-b induces Id1 and
promotes CSC self-renewal (Anido et al.,
2010). How can we reconcile the factthat BMP acts as a differentiation cyto-
kine while inducing the expression of
Id1? Further research is warranted to
fully understand the role of BMP in CSC
biology.
The work from Yan et al. (2014) begins
to explain the molecular mechanisms
implicated in the finely regulated balance
between CSC self-renewal and differenti-
ation. This phenomenon is at the core
of the intratumoral heterogeneity caused
by cell differentiation and has critical ther-
apeutic implications. The interplay be-
tween CSCs and non-CSCs is considered
to regulate the ability of tumors to re-
initiate. Therapies tackling the balance
between CSC self-renewal and differenti-
ation are needed to prevent CSC-depen-
dent reinitiation of tumors in the same
primary location (relapse) or in a distant
location (metastasis). Moreover, the in-
duction of CSC differentiation mightCancer Cell 25, June 16sensitize tumors to chemo-
and radiotherapy, because
CSCs are more resistant to
these types of DNA damage-
inflicting treatments. In this
context, Gremlin1 appears to
be a very interesting thera-
peutic target in GBM, and
further work is needed to
assess whether the phar-
macological blockade of
Gremlin1 in isolation or in
combination with BMP might
provide hope against this
dismal disease.REFERENCES
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